More News

09 Sep 2021 PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation
09 Sep 2021 Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
09 Sep 2021 ProQR Announces Axiomer® RNA Editing Licensing and Research Collaboration with Lilly
09 Sep 2021 Sanofi to acquire Kadmon to further strengthen growth of transplant business
07 Sep 2021 NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington's Disease
07 Sep 2021 Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
07 Sep 2021 National Cancer Institute (NCI) Awards Isoprene Pharmaceuticals, Inc. a Two-Year $2 Million Small Business Innovation Research (SBIR) Grant
03 Sep 2021 Evotec announces Bristol Myers Squibb opt-in of EVT8683 as the first programme from iPSC-based neurodegeneration collaboration
02 Sep 2021 Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
31 Aug 2021 Adaptive Phage Therapeutics Announces Licensing Agreement with the Walter Reed Army Institute of Research
30 Aug 2021 Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
26 Aug 2021 NovaRock Biotherapeutics Announces Exclusive License Agreement and Strategic Partnership with Flame BioSciences
25 Aug 2021 Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia
24 Aug 2021 Shape Therapeutics enters into a strategic research collaboration with Roche to advance breakthrough AAV-based RNA editing technology for neuroscience and rare disease indications
24 Aug 2021 AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics
24 Aug 2021 Abveris and Abilita Bio Announce a Discovery Collaboration to Develop Therapeutics for Challenging Membrane Protein Targets
24 Aug 2021 Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies
23 Aug 2021 Pfizer to Acquire Trillium Therapeutics Inc.
19 Aug 2021 Jnana Therapeutics closes $50 million Series B financing to advance lead PKU program and small molecule pipeline based on next gen chemoproteomic platform
19 Aug 2021 Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
19 Aug 2021 Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases
18 Aug 2021 Alligator Bioscience announces Immuno-oncology Research Collaboration and License Agreement with Orion Corporation
18 Aug 2021 Navrogen Inc. and Tavotek Biotherapeutics Announce Strategic Collaboration to Improve Therapeutic Efficacy of Antibody Pipeline Agents
11 Aug 2021 GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
10 Aug 2021 Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up